Search results for " stomach"

showing 10 items of 37 documents

Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA‐DR and DQ allele frequency

2007

OBJECTIVE: To investigate the relationship of the polymorphic enhancer HS1,2 central to the 3' enhancer complex regulatory region (IgH3'EC) of the immunoglobulin heavy chain genes with systemic sclerosis (SSc) disease and compare it with HLA-DR and DQ associations. METHODS: A total of 116 patients with SSc were classified as diffuse (dSSc) or limited (lSSc), and as carriers of antitopoisomerase I (anti-Scl70) or anticentromere (ACA) antibodies. Allele and genotype frequencies were assessed in the population as a whole and in the two major subsets, dSSc and lSSc. The concentration of peripheral blood immunoglobulin levels was also determined and analysed according to the genotypes. RESULTS: …

MaleSettore MED/16 - REUMATOLOGIAsystemic sclerosisclinical evaluationgenotype phenotype correlationHLA DR antigenSclerodermaGene FrequencyGenotypeImmunology and Allergycentromere antibody; HLA DR antigen; immunoglobulin enhancer binding protein; scl 70 antibody; adult; aged; article; clinical evaluation; controlled study; DNA polymorphism; female; gene frequency; genotype phenotype correlation; human; major clinical study; male; priority journal; risk factor; systemic sclerosis; Adult; Aged; Autoantibodies; Enhancer Elements (Genetics); Esophagus; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; HLA-DQ Antigens; HLA-DR Antigens; Humans; Immunoglobulin Heavy Chains; Male; Middle Aged; Phenotype; Polymorphism Genetic; Scleroderma Systemic; Statistics Nonparametric; Stomacheducation.field_of_studycentromere antibodyStatisticsStomacharticleMiddle AgedExtended Reportimmunoglobulin enhancer binding proteinEnhancer Elements GeneticPhenotypepriority journalrisk factorFemaleImmunoglobulin Heavy ChainsAdultGenotypeImmunologyPopulationBiologyGeneral Biochemistry Genetics and Molecular BiologyStatistics NonparametricEsophagusGeneticRheumatologyHLA-DQ AntigensHLA-DRHumanscontrolled studyEnhancer Elements (Genetics)NonparametricGenetic Predisposition to DiseasehumanPolymorphismAlleleeducationEnhancerAllele frequencyAgedAutoantibodiesscl 70 antibodyPolymorphism GeneticScleroderma SystemicSystemicHLA-DR Antigensmajor clinical studyGenotype frequencySettore BIO/18 - GeneticaDNA polymorphismImmunologyImmunoglobulin heavy chain
researchProduct

The SIC-GIRCG 2013 Consensus Conference on Gastric Cancer.

2014

Abstract The topic chosen by the Board of the Italian Society of Surgery for the 2013 annual Consensus Conference was gastric cancer. With this purpose, under the direction of 2 chairmen, 36 experts nominated by the Regional Societies of Surgery and by the Italian Research Group for Gastric Cancer (GIRCG) participated in an experts consensus exercise, preceded by a questionnaire and mainly held by telematic vote, in accordance with the rules of the Delphi method. The results of this Consensus Conference, presented to the 115th National Congress of the Italian Society of Surgery, and approved in plenary session, are reported in the present paper.

Malemedicine.medical_specialtyGastric cancer Surgery Chemotherapy Staging Endoscopy LaparoscopyStagingDelphi TechniqueMEDLINEDelphi methodchemotherapyEndosonographyDelphi Technique; Endosonography; Female; Humans; Italy; Lymph Node Excision; Male; Neoplasm Staging; Societies Medical; Stomach NeoplasmsStomach NeoplasmStomach NeoplasmsMedicalmedicineHumanslapaoscopyguidelinesgastric cancer; chemotherapy; staging endoscopy; lapaoscopySocieties MedicalNeoplasm StagingSettore MED/06 - ONCOLOGIA MEDICAtreatmentbusiness.industryConsensus conferenceCancerEndoscopymedicine.diseasePlenary sessionSurgerySettore MED/18 - Chirurgia GeneraleGastric CancerItalyLymph Node ExcisionNeoplasm stagingLaparoscopySurgeryFemaleguidelines; Gastric Cancer; treatmentbusinessSocietiesstaging endoscopyHuman
researchProduct

Guanosine negatively modulates the gastric motor function in mouse

2013

The aim of the present study was to evaluate if guanine-based purines may affect the gastric motor function in mouse. Thus, the influence of guanosine on the gastric emptying rate in vivo was determined and its effects on spontaneous gastric mechanical activity, detected as changes of the intraluminal pressure, were analyzed in vitro before and after different treatments. Gastric gavage of guanosine (1.75-10 mg/kg) delayed the gastric emptying. Guanosine (30 μM-1 mM) induced a concentration-dependent relaxation of isolated stomach, which was not affected by the inhibition of the purine nucleoside phosphorylase enzyme by 4'-deaza-1'-aza-2'-deoxy-1'-(9-methylene)-immucillin-H. The inhibitory …

Malemedicine.medical_specialtyPurine nucleoside phosphorylaseGuanosineAdenosine receptor antagonistSettore BIO/09 - FisiologiaAdenylyl cyclaseMiceCellular and Molecular Neurosciencechemistry.chemical_compoundInternal medicineCyclic AMPmedicineAnimalsCyclic adenosine monophosphateMolecular BiologyDose-Response Relationship DrugGuanosineGastric emptyingChemistryStomachMuscle SmoothCell BiologyAdaptation PhysiologicalAdenosine receptorMice Inbred C57BLguanosine stomach relaxationEndocrinologyGastric EmptyingOriginal ArticleGastrointestinal MotilitySoluble guanylyl cyclasePurinergic Signalling
researchProduct

Chemotherapy for advanced gastric cancer

2017

Background Gastric cancer is the fifth most common cancer worldwide. In "Western" countries, most people are either diagnosed at an advanced stage, or develop a relapse after surgery with curative intent. In people with advanced disease, significant benefits from targeted therapies are currently limited to HER-2 positive disease treated with trastuzumab, in combination with chemotherapy, in first-line. In second-line, ramucirumab, alone or in combination with paclitaxel, demonstrated significant survival benefits. Thus, systemic chemotherapy remains the mainstay of treatment for advanced gastric cancer. Uncertainty remains regarding the choice of the regimen. Objectives To assess the effica…

Medicine General & Introductory Medical Sciences0301 basic medicineOncologymedicine.medical_specialtymedicine.medical_treatmentDocetaxelIrinotecanRamucirumab03 medical and health sciences0302 clinical medicineStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineAnthracyclinesPharmacology (medical)Randomized Controlled Trials as TopicChemotherapyPerformance statusbusiness.industryCombination chemotherapyOxaliplatinSurgeryRegimenAnthracyclines/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Camptothecin/administration & dosage; Camptothecin/analogs & derivatives; Cisplatin/administration & dosage; Fluorouracil/administration & dosage; Humans; Randomized Controlled Trials as Topic; Stomach Neoplasms/drug therapy; Stomach Neoplasms/mortality; Taxoids/administration & dosage030104 developmental biologyDocetaxel030220 oncology & carcinogenesisCamptothecinTaxoidsFluorouracilCisplatinbusinessEpirubicinmedicine.drugCochrane Database of Systematic Reviews
researchProduct

NANC inhibitory neurotransmission in mouse isolated stomach: Involvement of nitric oxide, ATP and vasoactive intestinal polypeptide

2003

1. The neurotransmitters involved in NANC relaxation and their possible interactions were investigated in mouse isolated stomach, recording the motor responses as changes of endoluminal pressure from whole organ. 2. Field stimulation produced tetrodotoxin-sensitive, frequency-dependent, biphasic responses: rapid transient relaxation followed by a delayed inhibitory component. 3. The inhibitor of the synthesis of nitric oxide (NO), L-NAME, abolished the rapid relaxation and significantly reduced the slow relaxation. Apamin, blocker of Ca 2+-dependent K + channels, or ADPβS, which desensitises P 2y purinoceptors, reduced the slow relaxation to 2-8 Hz, without affecting that to 16-32 Hz or the…

NitroprussideMuscle RelaxationNANC inhibitory neurotransmitterNitric OxideSynaptic TransmissionSettore BIO/09 - FisiologiaGastric relaxationMiceAdenosine TriphosphateAdrenergic FiberChymotrypsinEnzyme InhibitorThionucleotideCholinergic FiberPharmacologyDose-Response Relationship DrugAnimalIn Vitro TechniqueMouse stomachStomachNitric Oxide DonorElectric StimulationATPVIPAdenosine DiphosphateMice Inbred C57BLNG-Nitroarginine Methyl EsterApaminReceptors Vasoactive Intestinal PeptideNitric Oxide SynthaseVasoactive Intestinal Peptide
researchProduct

Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey

2013

BackgroundBone metastasis represents an increasing clinical problem in advanced gastric cancer (GC) as disease-related survival improves. In literature, few data on the natural history of bone disease in GC are available.Patients and methodsData on clinicopathology, skeletal outcomes, skeletal-related events (SREs), and bone-directed therapies for 208 deceased GC patients with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 8 months (CI 95%, 6.125-9.875 months) considering all included patients. Median number of SREs/patient was one. Less than half of the patients (31%) experienced at least one and only 4 and 2% experienced at least two and …

OncologyAdultMalemedicine.medical_specialtyPathologyBone diseaseSettore MED/06 - Oncologia Medicamedicine.medical_treatmentScienceBone NeoplasmsMetastasisgastric cancer; bone metastasisStomach NeoplasmsInternal medicinemedicineHumansskeletal disease advanced hepatocellular carcinomaskeletal-related events bisphosphonateAdult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Patient Outcome Assessment; Population Surveillance; Prognosis; Retrospective Studies; Stomach NeoplasmsNeoplasm Metastasisbone metastasisAgedRetrospective StudiesMultidisciplinaryBone Density Conservation AgentsDiphosphonatesbusiness.industrygastric cancerQRBone metastasisCancerBone fractureMiddle Agedmedicine.diseasePrognosisRadiation therapyPatient Outcome AssessmentBone Density Conservation AgentsZoledronic acidPopulation SurveillanceMedicineFemalebusinessmedicine.drugResearch Article
researchProduct

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differ…

2012

The 1st St. Gallen EORTC Gastrointestinal Cancer Conference 2012 Expert Panel clearly differentiated treatment and staging recommendations for the various gastroesophageal cancers. For locally advanced gastric cancer (>= PT3N+), the preferred treatment modality was pre- and postoperative chemotherapy. The majority of panel members would also treat T2N+ or even T2N0 tumours with a similar approach mainly because pretherapeutic staging was considered highly unreliable. It was agreed that adenocarcinoma of the gastroesophageal junction (AEG) is classified best according to Siewert et al. Preoperative radiochemotherapy (RCT) is the preferred treatment for AEG type I and II tumours. For AEG type…

OncologyCancer Researchmedicine.medical_specialtyEsophageal Neoplasmspathology/surgery/therapymedicine.medical_treatmentAdenocarcinoma; pathology/surgery/therapy Carcinoma; Squamous Cell; pathology/surgery/therapy Chemoradiotherapy; Adjuvant Chemotherapy; Adjuvant Early Detection of Cancer Esophageal Neoplasms; pathology/surgery/therapy Esophagectomy Esophagogastric Junction; pathology/surgery Gastrectomy Humans Neoadjuvant Therapy Neoplasm Staging Predictive Value of Tests Stomach Neoplasms; pathology/surgery/therapy Treatment OutcomePredictive Value of TestAdenocarcinomaSDG 3 - Good Health and Well-beingPredictive Value of TestsStomach NeoplasmsGastrectomyStomach NeoplasmInternal medicineCarcinomamedicineHumansChemotherapyGastrointestinal cancerEsophageal NeoplasmLymph nodeAdjuvantEarly Detection of CancerNeoadjuvant therapyNeoplasm Stagingpathology/surgerybusiness.industryCarcinomaCancerChemoradiotherapy AdjuvantChemoradiotherapymedicine.diseaseNeoadjuvant TherapyEsophagectomyTreatment Outcomemedicine.anatomical_structureSquamous CellOncologyChemotherapy AdjuvantEsophagectomyCarcinoma Squamous CellAdenocarcinomaEsophagogastric JunctionbusinessChemoradiotherapyHuman
researchProduct

Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Onc…

2009

Purpose: This phase II trial assessed the tolerability and efficacy of a triplet of oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer. Methods: Patients with unresectable or metastatic gastric cancer, unexposed to palliative chemotherapy, received oxaliplatin 85 mg/m 2 iv and irinotecan 150 mg/m2 iv on day 1, 6S-folinic acid 250 mg/m2 iv and fluorouracil 750 mg/m2 iv on day 2, every 2 weeks. Response rate (RR) was assessed after a minimum of four cycles, and treatment continued up to 12 cycles. Results: Sixty-three patients were treated, with a median of eight (range 1-12) cycles/patient. Two complete and 19 partial responses were registered (RR 33% [95% CI, …

OncologyMaleCancer ResearchOrganoplatinum CompoundsAntimetabolitesSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntidotesLeucovorinKaplan-Meier EstimateToxicologyPhytogenicAntineoplastic Combined Chemotherapy Protocols80 and overMedicinePharmacology (medical)Stomach cancerTomographyAged 80 and overMiddle AgedAntineoplasticMagnetic Resonance ImagingX-Ray ComputedOxaliplatinOncologyFluorouracilFemaleFluorouracilmedicine.drugAdultmedicine.medical_specialtyAntimetabolites AntineoplasticAntineoplastic AgentsNeutropeniaAdenocarcinomaIrinotecanFolinic acidStomach NeoplasmsTomography X-Ray Computed; Male; Aged 80 and over; Antimetabolites Antineoplastic; Middle Aged; Kaplan-Meier Estimate; Camptothecin; Survival Analysis; Female; Fluorouracil; Adenocarcinoma; Leucovorin; Humans; Organoplatinum Compounds; Antineoplastic Agents; Stomach Neoplasms; Magnetic Resonance Imaging; Antidotes; Blood Cell Count; Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Agents Phytogenic; Aged; AdultInternal medicineHumansAgedPharmacologyChemotherapybusiness.industryGastric cancerFluorouracilIrinotecan OxaliplatinTriplet regimenmedicine.diseaseAntineoplastic Agents PhytogenicSurvival Analysisdigestive system diseasesOxaliplatinBlood Cell CountIrinotecanCamptothecinbusinessTomography X-Ray ComputedFebrile neutropeniaCancer chemotherapy and pharmacology
researchProduct

[Regular Paper] Detection of H. pylori Induced Gastric Inflammation by Diffuse Reflectance Analysis

2018

Spectral acquisitions contain rich information and thus, are promising modalities for early detection of gastric diseases. In this study, we analyze the diffuse reflectance of the gastric inflammatory lesions induced by the bacterium H. pylori in the mouse stomach. A pipeline has been designed to characterize and classify spectra acquired on mice. The pipeline is based on a band clustering algorithm followed by the computation of meaningful division and subtraction features and by classification with a linear SVM classifier. Currently, the pipeline is able to recognize inflamed stomach's spectra with an accuracy of 98%. These results are promising and the same pipeline could be adapted for …

Pathologymedicine.medical_specialtybiologybusiness.industryStomachdigestive oral and skin physiologyLinear svmSubtractionEarly detectionInflammationHelicobacter pyloribiology.organism_classification01 natural sciencesGastric DiseasesMouse Stomach010309 optics03 medical and health sciences0302 clinical medicinemedicine.anatomical_structure030220 oncology & carcinogenesis0103 physical sciencesMedicinemedicine.symptombusiness2018 IEEE 18th International Conference on Bioinformatics and Bioengineering (BIBE)
researchProduct

Granular cell tumor of stomach: a case report and review of literature.

2006

Granular cell tumor (GCT) was described for the first time by Abrikosoff in 1926. It is a relatively rare neoplasm that may occur at many sites, but most commonly in the skin or soft tissues. The occurrence of GCT in the gastrointestinal tract is rare, accounting approximately for 8% of all tumors, among which the most common site is the esophagus, whereas gastric localization is very rare. Gastric GCTs can be solitary or, more frequently, associated with other gastrointestinal localization. Although GCTs are usually clinically and histologically benign, some malignant cases have been reported. Histologically, these tumors consist of polygonal and fusiform cells disposed in compact "nests" …

Pathologymedicine.medical_specialtymedicine.medical_treatmentCase ReportEndoscopy GastrointestinalStomach NeoplasmsmedicineNeoplasmHumansEsophagusGranular cell tumorGastrointestinal tractbusiness.industryStomachS100 ProteinsGastroenterologySoft tissueGeneral MedicineWedge resectionMiddle Agedmedicine.diseaseImmunohistochemistrymedicine.anatomical_structureGranular Cell TumorImmunohistochemistryFemalebusinessBenign Granular cell tumor Stomach Surgical resectionWorld journal of gastroenterology
researchProduct